Transcripta Bio
Agent49Agent Readiness: 49/100. Top 25%. Measured by StartupHub.ai. Median 41.Trust72Data Trust: 72/100. Above median. Measured by StartupHub.ai. Median 61.AI-powered drug discovery company focused on neurological and neuromuscular diseases, leveraging transcriptomics to accelerate therapeutic development.
About
Transcripta Bio is an AI-powered drug discovery company dedicated to developing novel therapeutics for neurological and neuromuscular diseases. The company's closed-loop discovery engine uses transcriptomic signature matching to identify drug candidates whose molecular signatures are the inverse of patient-derived disease signatures, enabling a faster, more capital-efficient path to the clinic. They also leverage their proprietary AI model, Conductor AI, to predict new drugs that move gene expression as appropriate.
Key facts
At-a-glance profile data
- Website
- transcriptabio.com
- Headquarters
- Palo Alto, United States
- Founded
- 2023
- Total funding
- $24M (Series A)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 21 Jul 2026 | Series A | $24M | - |
Tech stack
Detected on transcriptabio.com, last scanned 15 Oct 2026. Run your own scan
- Frontend
- Next.js, Tailwind CSS
- Analytics
- Google Analytics 4
- Email provider
- Google Workspace
- Email marketing
- Substack
- Cookie consent
- Termly
Frequently asked
Is Transcripta Bio trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Transcripta Bio is 72 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Transcripta Bio raised?
Transcripta Bio has raised a total of $24M in funding. The most recent round on record is Series A.
